JWCTF.US JW (Cayman) Therapeutics Co. Ltd

Healthcare Biotechnology USA Stocks
0.2022 USD
Close of Nov 15, 2026
0.2022 0.4523
Market cap
USD 84.3M
P/E
-
P/B
1.25x
ROE
-44.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is JWCTF.US undervalued?

Graham number

The Graham number of JW (Cayman) Therapeutics Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

JW (Cayman) Therapeutics Co. Ltd fundamental analysis

No fundamental analysis for JW (Cayman) Therapeutics Co. Ltd yet.

JW (Cayman) Therapeutics Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel in…

Full company profile